Shots:
- Nektar presents two nonclinical data presentations for NKTR-255 at the 62nd ASH Annual Meeting, which include an oral presentation of translational research studies conducted in collaboration with researchers from Dana-Farber Cancer Center
- NKTR-255 is being tested in a P-Ib/II study as monothx. & in combination with rituximab or daratumumab in patients with MM & NHL and being evaluated in a P-Ib/II trial in combination with cetuximab for the treatment of colorectal cancer & HNSCC
- NKTR-255 is an IL-15 receptor agonist designed to activate the IL-15 pathway & expand NK cell, promoting the survival & expansion of memory CD8+ T cells without inducing suppressive regulatory T cells
Click here to read full press release/ article | Ref: PRNewswire | Image: The Street
The post Nektar Therapeutics Presents Preclinical Data of NKTR-255 in P-Ib/II Study at ASH 2020 first appeared on PharmaShots.
